AVB-101, being studied in the ASPIRE-FTD clinical trial, is also an investigational gene-replacement therapy that utilizes AAV9 and intrathalamic delivery of the GRN gene (NCT06064890). The gene discussed is GRN; the disease is frontotemporal dementia.